Donald I. Abrams Joins NEMUS' SAB
This article was originally published in Scrip
Executive Summary
NEMUS Bioscience, Inc. has appointed Donald I. Abrams to its scientific advisory board (SAB). Abrams is currently professor of clinical medicine at the University of California and chief of the hematology-oncology division at San Francisco General Hospital. He is also an integrative oncologist at the U.C.S.F. Osher Center for Integrative Medicine and was co-editor of the Oxford University Press textbook of Integrative Oncology. Previously, Abrams was president of the Society of Integrative Oncology and is a member of the National Cancer Institute's (NCI) Physician Data Query: Complementary and Alternative Medicine editorial board.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.